Halozyme Therapeutics, Inc. HALO
Price alert —
Sign in to get a one-time email the moment HALO crosses your price. Free accounts included.
Sign in / create a free accountHalozyme Therapeutics, Inc. is a healthcare company listed in the US.
HALO last traded at $77.81, up 0.3% on the day; that's in the upper part of its 52-week range ($61.33–$82.26). Right now it's trading close to its recent average, with no strong stretch in either direction.
Earnings reports are the biggest scheduled catalysts to keep an eye on, and day to day, watch whether it holds above or slips below its recent average.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
On the latest daily bar, momentum sits mid-range (RSI 59), the trend is quiet (ADX 24), and trading is light at 0.7× normal volume. On the business side, revenue is growing 42% year over year and the business keeps about 16 cents of every sales dollar as free cash.
Latest-bar indicator readings behind the grade — display-only, they don't move the letter.
Company fundamentals for context — display-only, they don't move the grade.
Our cash-flow model pegs fair value near $90.55 (fair range $35–$91); today's price leaves a +16% cushion below that estimate. The model's verdict is “Undervalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.
- ✓ Quick ratio 4.25 (antifragile)
- ✓ Current ratio 4.66 (antifragile)
- ✓ Positive retained earnings
- ✓ Gross margin 77% (pricing power)
- ⚠ Debt exceeds cash
- ⚠ Debt/equity 50.73 (fragile)
- ⚠ Receivables growing faster than revenue
Price implies ~22% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
HALO is a $9.2 billion company, priced at 27× last year's earnings.